Nguyen Phuoc Long1, Sang Jun Yoon1, Nguyen Hoang Anh1, Tran Diem Nghi2, Dong Kyu Lim1, Yu Jin Hong1, Soon-Sun Hong3, Sung Won Kwon4. 1. Research Institute of Pharmaceutical Sciences and College of Pharmacy, Seoul National University, Seoul, 08826, South Korea. 2. School of Medicine, Vietnam National University, Ho Chi Minh City, 700000, Vietnam. 3. Department of Drug Development, College of Medicine, Inha University, Incheon, 22212, South Korea. 4. Research Institute of Pharmaceutical Sciences and College of Pharmacy, Seoul National University, Seoul, 08826, South Korea. swkwon@snu.ac.kr.
Abstract
INTRODUCTION: Metabolomics is an emerging approach for early detection of cancer. Along with the development of metabolomics, high-throughput technologies and statistical learning, the integration of multiple biomarkers has significantly improved clinical diagnosis and management for patients. OBJECTIVES: In this study, we conducted a systematic review to examine recent advancements in the oncometabolomics-based diagnostic biomarker discovery and validation in pancreatic cancer. METHODS: PubMed, Scopus, and Web of Science were searched for relevant studies published before September 2017. We examined the study designs, the metabolomics approaches, and the reporting methodological quality following PRISMA statement. RESULTS AND CONCLUSION: The included 25 studies primarily focused on the identification rather than the validation of predictive capacity of potential biomarkers. The sample size ranged from 10 to 8760. External validation of the biomarker panels was observed in nine studies. The diagnostic area under the curve ranged from 0.68 to 1.00 (sensitivity: 0.43-1.00, specificity: 0.73-1.00). The effects of patients' bio-parameters on metabolome alterations in a context-dependent manner have not been thoroughly elucidated. The most reported candidates were glutamic acid and histidine in seven studies, and glutamine and isoleucine in five studies, leading to the predominant enrichment of amino acid-related pathways. Notably, 46 metabolites were estimated in at least two studies. Specific challenges and potential pitfalls to provide better insights into future research directions were thoroughly discussed. Our investigation suggests that metabolomics is a robust approach that will improve the diagnostic assessment of pancreatic cancer. Further studies are warranted to validate their validity in multi-clinical settings.
INTRODUCTION: Metabolomics is an emerging approach for early detection of cancer. Along with the development of metabolomics, high-throughput technologies and statistical learning, the integration of multiple biomarkers has significantly improved clinical diagnosis and management for patients. OBJECTIVES: In this study, we conducted a systematic review to examine recent advancements in the oncometabolomics-based diagnostic biomarker discovery and validation in pancreatic cancer. METHODS: PubMed, Scopus, and Web of Science were searched for relevant studies published before September 2017. We examined the study designs, the metabolomics approaches, and the reporting methodological quality following PRISMA statement. RESULTS AND CONCLUSION: The included 25 studies primarily focused on the identification rather than the validation of predictive capacity of potential biomarkers. The sample size ranged from 10 to 8760. External validation of the biomarker panels was observed in nine studies. The diagnostic area under the curve ranged from 0.68 to 1.00 (sensitivity: 0.43-1.00, specificity: 0.73-1.00). The effects of patients' bio-parameters on metabolome alterations in a context-dependent manner have not been thoroughly elucidated. The most reported candidates were glutamic acid and histidine in seven studies, and glutamine and isoleucine in five studies, leading to the predominant enrichment of amino acid-related pathways. Notably, 46 metabolites were estimated in at least two studies. Specific challenges and potential pitfalls to provide better insights into future research directions were thoroughly discussed. Our investigation suggests that metabolomics is a robust approach that will improve the diagnostic assessment of pancreatic cancer. Further studies are warranted to validate their validity in multi-clinical settings.
Authors: Warwick B Dunn; David Broadhurst; Paul Begley; Eva Zelena; Sue Francis-McIntyre; Nadine Anderson; Marie Brown; Joshau D Knowles; Antony Halsall; John N Haselden; Andrew W Nicholls; Ian D Wilson; Douglas B Kell; Royston Goodacre Journal: Nat Protoc Date: 2011-06-30 Impact factor: 13.491
Authors: Tobias Kind; Hiroshi Tsugawa; Tomas Cajka; Yan Ma; Zijuan Lai; Sajjan S Mehta; Gert Wohlgemuth; Dinesh Kumar Barupal; Megan R Showalter; Masanori Arita; Oliver Fiehn Journal: Mass Spectrom Rev Date: 2017-04-24 Impact factor: 10.946
Authors: Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les Irwig; Jeroen G Lijmer; David Moher; Drummond Rennie; Henrica C W de Vet; Herbert Y Kressel; Nader Rifai; Robert M Golub; Douglas G Altman; Lotty Hooft; Daniël A Korevaar; Jérémie F Cohen Journal: Radiology Date: 2015-10-28 Impact factor: 11.105
Authors: Clara Pérez-Rambla; Leonor Puchades-Carrasco; María García-Flores; José Rubio-Briones; José Antonio López-Guerrero; Antonio Pineda-Lucena Journal: Metabolomics Date: 2017-03-09 Impact factor: 4.290
Authors: Vijayasarathy Ketavarapu; Vishnubhotla Ravikanth; Mitnala Sasikala; G V Rao; Ch Venkataramana Devi; Prabhakar Sripadi; Murali Satyanarayana Bethu; Ramars Amanchy; H V V Murthy; Stephen J Pandol; D Nageshwar Reddy Journal: BMC Cancer Date: 2022-07-19 Impact factor: 4.638
Authors: Daniel R Schmidt; Rutulkumar Patel; David G Kirsch; Caroline A Lewis; Matthew G Vander Heiden; Jason W Locasale Journal: CA Cancer J Clin Date: 2021-05-13 Impact factor: 286.130
Authors: Tabassum A Khan; Tyler J Loftus; Amanda C Filiberto; Tezcan Ozrazgat-Baslanti; Matthew M Ruppert; Sabyasachi Bandyopadhyay; Evagelia C Laiakis; Dean J Arnaoutakis; Azra Bihorac Journal: Ann Surg Date: 2021-02-01 Impact factor: 13.787